Welcome to our dedicated page for Adagio Medical Holdings SEC filings (Ticker: ADGM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Adagio Medical Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Adagio Medical Holdings's regulatory disclosures and financial reporting.
Adagio Medical Holdings, Inc. is holding a virtual 2026 annual stockholder meeting on June 16, 2026 at 10:00 a.m. Pacific Time. Stockholders of record as of April 24, 2026 may attend and vote online using a control number.
Investors will vote on electing two Class II directors, Orly Mishan and Sean Salmon, to three-year terms and on ratifying WithumSmith+Brown, PC as independent registered public accounting firm for the year ending December 31, 2026. The board is classified into three staggered classes and currently has seven members, with an independent non-executive chair.
The proxy details governance practices, including fully independent key committees, an insider trading and anti-hedging policy, and a Dodd-Frank–compliant clawback policy. For 2025, CEO Todd Usen received total compensation of $2,500,473 and CFO Deborah Kaster received $836,037, primarily from salary and stock options. As of April 24, 2026, 22,210,459 shares of common stock were outstanding, with entities affiliated with Perceptive Advisors LLC holding 55.4% of the stock.
Adagio Medical Holdings announced positive pivotal six‑month results from its -VT IDE trial of the vCLAS ventricular ablation system for treating ventricular tachycardia (VT). The study enrolled 209 patients with structural heart disease and met both safety and effectiveness endpoints, showing 84% freedom from ICD shock and 59% freedom from VT recurrence.
The trial included both ischemic and non‑ischemic cardiomyopathy patients, who achieved equivalent outcomes using an endocardial‑only ablation approach. Major adverse events occurred in 2.4% of patients, including 1.9% peri‑procedural deaths, with only 1.0% adjudicated as possibly device‑related. The company plans to use these data to support an FDA premarket approval application for vCLAS.
Adagio Medical Holdings, Inc. has scheduled its 2026 Annual Meeting of Stockholders for June 16, 2026. Stockholders of record at the close of business on April 24, 2026 will be entitled to receive notice of, and vote at, the meeting.
Stockholder proposals and director nominations must be received by the Company’s Secretary by April 30, 2026 to be considered, including proposals under Rule 14a-8 and notices required by the Company’s bylaws and the SEC’s universal proxy rules.
Adagio Medical Holdings, Inc. reported that the FDA has granted Investigational Device Exemption (IDE) approval to expand its -VT trial to study the next-generation vCLAS Ultra-Low Temperature Ablation (ULTA) Ventricular Ablation System for treating sustained monomorphic ventricular tachycardia. The IDE expansion allows a prospective, single-arm, multi-center sub-study of up to 55 patients with scar-mediated VT in ischemic and non-ischemic cardiomyopathy. The new vCLAS Ultra catheter targets ablation temperatures near -170°C and has shown over 50% reductions in ablation time in pre-clinical models, aiming to deliver deeper lesions, shorter procedure times, and improved usability on Adagio’s established endocardial ULTA platform.
Adagio Medical Holdings, Inc. filed Post-Effective Amendment No. 2 to its Registration Statement (File No. 333-284266) to correct Exhibit 23.4 by replacing an unsigned consent from WithumSmith+Brown, PC with the proper signed consent. The amendment states no other changes to the registration statement or prospectus.
Adagio Medical Holdings, Inc. filed Post-Effective Amendment No. 2 to its Registration Statement (File No. 333-284263) to correct Exhibit 23.4, the consent of its independent registered public accounting firm. The amendment replaces an unsigned consent previously filed and makes no other changes to the registration statement or prospectus.
Adagio Medical Holdings, Inc. filed a Post-Effective Amendment converting its previously effective Form S-1 into a Form S-3 shelf registration to permit resale of up to 31,818,652 shares of Common Stock by selling stockholders, comprised of Registration Delay Shares, Convertible Note Shares and Warrant Shares.
The prospectus states the Company will not receive proceeds from resales except up to an aggregate of $14.4 million if all warrants are exercised for cash. Shares outstanding were 22,210,459 as of March 23, 2026; pro forma assuming full conversion/exercise would be 53,955,778. The filing notes the market price was $1.15 per share as of March 31, 2026 and warns that resale or perceived resale could materially pressure the share price.